Eli Lilly and Company / Engage Biologics, Inc.

Non-Viral Genetic Medicines (Hemophilia A and Hepatocellular Carcinoma)

25K US cases/yr · $1.6B 2025 North America hemophilia gene therapy market

Disease Overview

Genetic medicines aim to deliver functional DNA or RNA to disease-relevant tissues to restore missing protein expression or modulate gene function. Viral-vector gene therapies (AAV, lentivirus) deliver high-potency genetic payloads but face well-documented limitations: immunogenicity that precludes redosing, cargo-size constraints, manufacturing complexity, and durability erosion in dividing tissues. Non-viral delivery via lipid nanoparticles (LNPs) — validated commercially through mRNA COVID-19 vaccines and Onpattro (patisiran) — offers redosability, simpler manufacturing, and lower immunogenicity but historically suffers from short DNA expression duration and weak nuclear localization. Hemophilia A, caused by F8 mutations affecting factor VIII production, affects approximately 16,000-25,000 US patients and has seen FDA-approved AAV gene therapy (BioMarin's Roctavian, 2023) struggle commercially due to weak uptake, durability concerns, and pricing. Hepatocellular carcinoma (HCC) is the most common primary liver cancer with approximately 41,000 new US cases annually, and remains a high-unmet-need indication where in situ gene therapy could complement systemic checkpoint and TKI regimens. Engage Biologics' Tethosome platform targets both as proof-of-concept indications, combining LNP-delivered DNA payloads with mRNA-encoded DNA-binding proteins that promote nuclear trafficking and sustained episomal expression.

Competitive Landscape

Non-viral genetic medicine delivery is dominated by LNP-mRNA platforms (Moderna, BioNTech, Arcturus) and emerging DNA-LNP entrants. In hemophilia A specifically, BioMarin's AAV-vectored Roctavian holds the only FDA-approved gene therapy slot but has experienced weak commercial uptake — analysts originally modeled $2.2B peak sales and BioMarin has signaled willingness to divest the franchise. Pfizer's Beqvez (fidanacogene elaparvovec) competes in hemophilia B. Engage Biologics' Tethosome differentiates on three vectors: (1) LNP delivery enabling redosing versus single-shot AAV; (2) mRNA-encoded DNA-binding protein that 'tethers' the DNA payload for nuclear trafficking and >100-fold expression boost; (3) cargo invisibility to innate immune DNA sensors. Lilly's $202M acquisition adds Engage's preclinical asset to a genetic medicine portfolio already strengthened through Verve ($1B), Orna ($2.4B), and Kelonia ($3.25B) acquisitions, positioning Lilly across viral and non-viral delivery modalities. The asset is preclinical with no disclosed clinical candidates.